NCT00674817View on ClinicalTrials.gov

An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 1, 2008

Primary Completion Date

October 1, 2008

Study Completion Date

October 19, 2008

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

400 microgrammes GSK961081

Inhaled GSK961081 administered via Dry Powder Inhaler.

DRUG

1200 microgrammes GSK961081

Inhaled GSK961081 adminisntered via dry powder inhaler.

Trial Locations (4)

6035

GSK Investigational Site, Wellington

40002

GSK Investigational Site, Khon Kaen

50200

GSK Investigational Site, Chiang Mai

M23 9LT

GSK Investigational Site, Manchester

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Theravance Biopharma

INDUSTRY

NCT00674817 - An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs. | Biotech Hunter | Biotech Hunter